Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBITDA: 2013-2025

Historic EBITDA for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' EBITDA fell 55.62% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 30.02%. This contributed to the annual value of $205.4 million for FY2024, which is 4.28% up from last year.
  • Amphastar Pharmaceuticals' EBITDA amounted to $25.3 million in Q3 2025, which was down 39.98% from $42.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' EBITDA ranged from a high of $72.7 million in Q3 2023 and a low of $10.3 million during Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' EBITDA averaged around $46.1 million, with its median value being $45.1 million (2024).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBITDA soared by 742.38% in 2021, and later plummeted by 55.62% in 2025.
  • Amphastar Pharmaceuticals' EBITDA (Quarterly) stood at $24.3 million in 2021, then skyrocketed by 56.00% to $37.8 million in 2022, then surged by 42.68% to $54.0 million in 2023, then decreased by 16.37% to $45.1 million in 2024, then tumbled by 55.62% to $25.3 million in 2025.
  • Its last three reported values are $25.3 million in Q3 2025, $42.2 million for Q2 2025, and $37.3 million during Q1 2025.